NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free PRPH Stock Alerts $6.47 +0.21 (+3.35%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$6.23▼$6.5550-Day Range$4.47▼$6.4752-Week Range$4.05▼$9.94Volume16,000 shsAverage Volume31,758 shsMarket Capitalization$116.78 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ProPhase Labs alerts: Email Address ProPhase Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside70.0% Upside$11.00 Price TargetShort InterestHealthy1.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.73) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector546th out of 939 stocksPharmaceutical Preparations Industry260th out of 441 stocks 3.5 Analyst's Opinion Consensus RatingProPhase Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, ProPhase Labs has a forecasted upside of 70.0% from its current price of $6.47.Amount of Analyst CoverageProPhase Labs has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.76% of the float of ProPhase Labs has been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in ProPhase Labs has recently decreased by 16.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRPH. Previous Next 2.8 News and Social Media Coverage News SentimentProPhase Labs has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ProPhase Labs this week, compared to 1 article on an average week.Search Interest2 people have searched for PRPH on MarketBeat in the last 30 days. MarketBeat Follows2 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders26.10% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.45% of the stock of ProPhase Labs is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProPhase Labs are expected to decrease in the coming year, from ($0.73) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About ProPhase Labs Stock (NASDAQ:PRPH)ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Read More PRPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRPH Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comProPhase Labs (NASDAQ:PRPH) Stock Passes Above 200 Day Moving Average of $4.77March 23, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for ProPhase Labs, Inc. (NASDAQ:PRPH) Lowered by HC WainwrightMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 20, 2024 | americanbankingnews.comProPhase Labs (NASDAQ:PRPH) Shares Cross Above 200 Day Moving Average of $4.69March 18, 2024 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | msn.comPRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023March 15, 2024 | globenewswire.comProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic InitiativesMarch 14, 2024 | benzinga.comProPhase Labs's Earnings: A PreviewMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 12, 2024 | msn.comDown 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%March 8, 2024 | globenewswire.comPROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024March 1, 2024 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 29% Above Their Intrinsic Value EstimateFebruary 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH) and Crispr Therapeutics AG (CRSP)February 21, 2024 | finance.yahoo.comDiamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)February 20, 2024 | finance.yahoo.comProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMARTFebruary 20, 2024 | finance.yahoo.comProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMARTFebruary 16, 2024 | finance.yahoo.comPRPH Mar 2024 5.000 putFebruary 15, 2024 | markets.businessinsider.comBuy Rating for Prophase Labs on Strong Clinical Trial Results and Manufacturing ExpansionFebruary 14, 2024 | finanznachrichten.deProPhase Labs, Inc.: ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement EquivirFebruary 14, 2024 | finance.yahoo.comProPhase Labs Announces Preliminary Positive Results for Dietary Supplement EquivirFebruary 14, 2024 | globenewswire.comProPhase Labs Announces Preliminary Positive Results for Dietary Supplement EquivirFebruary 8, 2024 | finance.yahoo.comDiamond Equity Research Releases In Depth Update Note on ProPhase Labs, Inc. (NASDAQ: PRPH) subsidiary, Pharmaloz Manufacturing, Inc. (PMI)January 30, 2024 | baystreet.caProPhase Dips on Moving Karkus up LadderJanuary 30, 2024 | finance.yahoo.comProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula GenomicsJanuary 23, 2024 | finanznachrichten.deProPhase Labs, Inc.: Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New ContractsJanuary 23, 2024 | finance.yahoo.comPharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New ContractsJanuary 13, 2024 | uk.investing.comProPhase Labs Inc (PRPH)See More Headlines Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRPH CUSIPN/A CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees129Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+70.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$18.46 million Net Margins-16.70% Pretax Margin-26.03% Return on Equity-17.51% Return on Assets-11.45% Debt Debt-to-Equity Ratio0.21 Current Ratio3.04 Quick Ratio2.73 Sales & Book Value Annual Sales$122.65 million Price / Sales0.95 Cash Flow$1.49 per share Price / Cash Flow4.35 Book Value$3.91 per share Price / Book1.65Miscellaneous Outstanding Shares18,050,000Free Float13,335,000Market Cap$116.78 million OptionableOptionable Beta-0.34 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Ted William Karkus (Age 65)Chairman & CEO Comp: $902.2kMr. Jed A. Latkin (Age 50)Chief Operating Officer & Head of Finance Department Mr. Robert A. Morse Jr. (Age 49)Controller, Principal Financial Officer & Principal Accounting Officer Mr. Sergio MirallesExecutive VP & Chief Information OfficerMr. Jason KarkusPresident of Nebula GenomicsMr. Kamal ObbadSenior VP and Director of Sales & Marketing - Nebula GenomicsMore ExecutivesKey CompetitorsSeres TherapeuticsNASDAQ:MCRBAllakosNASDAQ:ALLKSocietal CDMONASDAQ:SCTLSagimet BiosciencesNASDAQ:SGMTIO BiotechNASDAQ:IOBTView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 7,507 shares on 3/11/2024Ownership: 3.376%Goldman Sachs Group Inc.Sold 50,666 shares on 3/1/2024Ownership: 0.208%Vanguard Group Inc.Bought 7,507 shares on 2/15/2024Ownership: 3.376%Perritt Capital Management Inc.Sold 6,400 shares on 2/15/2024Ownership: 0.476%Citadel Advisors LLCSold 4,400 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions PRPH Stock Analysis - Frequently Asked Questions Should I buy or sell ProPhase Labs stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRPH shares. View PRPH analyst ratings or view top-rated stocks. What is ProPhase Labs' stock price target for 2024? 1 brokerages have issued 12-month target prices for ProPhase Labs' shares. Their PRPH share price targets range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 70.0% from the stock's current price. View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts. How have PRPH shares performed in 2024? ProPhase Labs' stock was trading at $4.52 at the beginning of 2024. Since then, PRPH stock has increased by 43.1% and is now trading at $6.47. View the best growth stocks for 2024 here. Are investors shorting ProPhase Labs? ProPhase Labs saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 248,200 shares, a decrease of 16.9% from the February 29th total of 298,500 shares. Based on an average daily trading volume, of 26,100 shares, the short-interest ratio is presently 9.5 days. Approximately 1.8% of the company's shares are short sold. View ProPhase Labs' Short Interest. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of $0.07 by $0.33. The business earned $9.47 million during the quarter, compared to the consensus estimate of $9.08 million. ProPhase Labs had a negative net margin of 16.70% and a negative trailing twelve-month return on equity of 17.51%. During the same period in the previous year, the business posted ($0.05) earnings per share. What is Ted Karkus' approval rating as ProPhase Labs' CEO? 2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH). Who are ProPhase Labs' major shareholders? ProPhase Labs' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.38%), Vanguard Group Inc. (3.38%), Perritt Capital Management Inc. (0.48%), Northern Trust Corp (0.25%), Goldman Sachs Group Inc. (0.21%) and Goldman Sachs Group Inc. (0.21%). View institutional ownership trends. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRPH) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.